Posted by Michael Wonder on 08 Apr 2020
Advanced Accelerator Applications announces Health Canada approval of Netspot diagnostic imaging agent kit to detect neuroendocrine tumours
7 April 2020 - Netspot is the first and only kit for the preparation of gallium (68 Ga) oxodotreotide injection for diagnostic imaging of neuroendocrine tumours.
Advanced Accelerator Applications today announced that Health Canada has approved Netspot (kit for the preparation of gallium (68Ga) oxodotreotide injection) for the evaluation of neuroendocrine tumours (“NETs”).
Netspot is the first and only kit for the preparation of gallium (68 Ga) oxodotreotide injection, a radioactive diagnostic agent for positron emission tomography (PET) imaging of somatostatin receptor over-expression in adult patients with confirmed or suspected somatostatin receptor positive neuroendocrine tumours (NETs) for localising primary tumours and their metastases.
